Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1843

Similar articles for PubMed (Select 15558585)


Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C.

Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P, Dawson S, Durazo F, Han S, Goldstein LI, Saab S, Hiatt J, Busuttil RW.

Liver Transpl. 2004 Dec;10(12):1478-86.


Misdiagnosed or Incidentally Detected Hepatocellular Carcinoma in Explanted Livers: Lessons Learned.

Abdelfattah MR, Abaalkhail F, Al-Manea H.

Ann Transplant. 2015 Jun 30;20:366-72. doi: 10.12659/AOT.893782.


Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Uygun Ilikhan S, Bilici M, Sahin H, Demir Akca AS, Can M, Oz II, Guven B, Buyukuysal MC, Ustundag Y.

World J Gastroenterol. 2015 Jun 14;21(22):6999-7007. doi: 10.3748/wjg.v21.i22.6999.


Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.

Wang D, Zhu ZZ, Jiang H, Zhu J, Cong WM, Wen BJ, He SQ, Liu SF.

Hepatol Int. 2015 Jul;9(3):438-46. doi: 10.1007/s12072-015-9642-0. Epub 2015 Jun 12.


Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis.

Lin HS, Wan RH, Gao LH, Li JF, Shan RF, Shi J.

Hepatobiliary Pancreat Dis Int. 2015 Jun;14(3):236-45.


Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.

Bodzin AS, Finn RS, Busuttil RW.

Hepatobiliary Pancreat Dis Int. 2015 Jun;14(3):234-5. No abstract available.


Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease.

Antoury C, Lopez R, Zein N, Stoller JK, Alkhouri N.

World J Hepatol. 2015 Jun 8;7(10):1427-32. doi: 10.4254/wjh.v7.i10.1427.


A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.

Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, Sangiovanni A, Ivarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet JM, Hoshida Y, Friedman SL.

Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655. [Epub ahead of print]


Incidentally discovered hepatocellular carcinoma in explanted liver: clinical, histopathologic features and outcome.

Madaleno J, Alves R, Silva N, Calretas S, Tomé L, Ferrão J, Barros A, Diogo D, Cipriano A, Furtado E, Carvalho A.

Transplant Proc. 2015 May;47(4):1051-4. doi: 10.1016/j.transproceed.2015.04.002.


Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.

Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS Jr.

Liver Cancer. 2015 Mar;4(2):115-25. doi: 10.1159/000367734.


Hepatocellular carcinoma tumor board: making sense of the technologies.

Abou-Alfa GK, Marrero J, Renz J, Lencioni R.

Am Soc Clin Oncol Educ Book. 2015;35:e213-20. doi: 10.14694/EdBook_AM.2015.35.e213.


Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.

Pang Q, Zhang JY, Xu XS, Song SD, Qu K, Chen W, Zhou YY, Miao RC, Liu SS, Dong YF, Liu C.

World J Gastroenterol. 2015 May 14;21(18):5607-21. doi: 10.3748/wjg.v21.i18.5607.


Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial.

Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, Tokumitsu Y, Hashimoto N, Tokuhisa Y, Sakamoto K, Sakai K, Suehiro Y, Hinoda Y, Tamada K, Yoshino S, Hazama S, Oka M.

Cancer Immunol Immunother. 2015 May 16. [Epub ahead of print]


Thioredoxin reductase: A novel, independent prognostic marker in patients with hepatocellular carcinoma.

Li C, Peng Y, Mao B, Qian K.

Oncotarget. 2015 Apr 23. [Epub ahead of print]


Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.

Lewin M, Gelu-Simeon M, Ostos M, Boufassa F, Sobesky R, Teicher E, Meyer L, Fontaine H, Salmon-Céron D, Samuel D, Seror O, Trinchet JC, Duclos-Vallée JC.

Radiology. 2015 May 6:141500. [Epub ahead of print]


Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.

Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2015 May 6. [Epub ahead of print]


IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study.

Kao JT, Feng CL, Yu CJ, Tsai SM, Hsu PN, Chen YL, Wu YY.

BMC Gastroenterol. 2015 Apr 25;15:50. doi: 10.1186/s12876-015-0283-5.


Predictors of tumor-free survival after liver transplant in patient with hepatocellular carcinoma.

Shamsaeefar A, Nikeghbalian S, Kazemi K, Gholami S, Motazedian N, Motazedian N, Fallahzadeh ME, Moini M, Gramizadeh B, Malekhosseini SA.

Exp Clin Transplant. 2015 Apr;13 Suppl 1:139-44.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk